June 13, 2025

Obicetrapib May Offer LDL Benefit

In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy.

Conexiant

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 13, 2025

Obicetrapib-Ezetimibe Combo Cuts LDL Nearly 50%

A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.

Conexiant

June 13, 2025

Lifestyle Interventions Recommended First-Line in Diabetes

A new guideline recommends using lifestyle interventions as first-line treatment to prevent, manage, and potentially reverse type 2 diabetes and prediabetes, supported by extensive clinical evidence.

Conexiant

June 13, 2025

The Special Series HPLC E-book

Are we still pushing the limits of liquid chromatography? Absolutely, say our experts – who continue to surf on the edge of LC innovation – as part of our special collection of recent HPLC insights.

The Analytical Scientist

June 12, 2025

Gene Variants Linked to CPPD Risk

A large genetic study in U.S. veterans has identified ENPP1 and RNF144B as genes associated with calcium pyrophosphate deposition disease, suggesting potential for targeted treatment approaches.

Conexiant

June 12, 2025

Smoking Cessation Drugs Show No Birth Risk

A large multinational cohort study found no increased risk of major congenital malformations associated with nicotine replacement therapy, varenicline, or bupropion use during early pregnancy.

Conexiant

June 12, 2025

Vegetarian Diet Linked to Lower Cancer Incidence

A large North American cohort study found that vegetarian diets were associated with lower risks of several site-specific cancers, including colorectal, stomach, breast, prostate, and lymphoproliferative cancers.

Conexiant

June 11, 2025

Simvastatin Lowers Cholesterol—but Does Not Improve Depression Symptoms

A randomized trial of 160 adults with depression and obesity found no improvement in mood symptoms from adding simvastatin to escitalopram, though the statin significantly lowered cholesterol and inflammation levels.

Conexiant